Description
Seeking infants aged up to 1 year with newly diagnosed B-acute lymphoblastic leukemia (B-ALL) or acute leukemia of ambiguous lineage (ALAL) that has not yet been treated for a study of adding an investigational drug to the usual chemotherapy.
Overview
Participants in this study will be treated with steroids for 7-10 days while genetic tests on the leukemia cells are being analyzed. Based on the results of the gene testing of the leukemia cells, participants will be placed into different groups to receive the usual chemotherapy for their type of leukemia and an investigational drug addition for a period of about 2.5 years.
What we're hoping for
We are studying if adding an investigational drug to the usual chemotherapy for infants with newly diagnosed B-acute lymphoblastic leukemia (B-ALL) or acute leukemia of ambiguous lineage (ALAL) is better or worse than the usual treatment alone.
Additional Information
ClinicalTrials.gov Identifier: NCT06317662